A Study of MGC026 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06242470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06242470
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MacroGenics
- Industry
- Enrollment
- 250 participants
Conditions and interventions
Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Bladder Cancer
- Breast Cancer
- Castration Resistant Prostatic Cancer
- Cervical Cancer
- Clear Cell Renal Cell Carcinoma
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Squamous Cell Cancer (SCC)
- Gastric Cancer
- Gastro-esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Metastatic Cancer
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Pancreas Cancer
- Platinum-resistant Ovarian Cancer
- Sarcoma
- Small-cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
Interventions
- MGC026 Dose Escalation Biological
- MGC026 Dose for Expansion Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2024
- Primary completion
- Apr 30, 2028
- Completion
- Sep 30, 2028
- Last update posted
- Feb 4, 2026
2024 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| START-New York Long Island | Lake Success | New York | 11042 | Recruiting |
| Providence Cancer Institute | Portland | Oregon | 97213 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06242470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06242470 live on ClinicalTrials.gov.